Open-to-Accrual Therapeutic Trials

Malignant Hematology

Protocol ID

Official Title

PI Name

Lead CRC

Disease Site


ADCT-402-103  NCT03684694

A Phase 1b Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma L. Bryan Sandra Wall Large B-Cell Lymphoma and Mantle Cell Lymphoma Ib

I137-102   NCT02931110

A Phase 1 Dose-Escalation and Cohort-Expansion Study of Intravenous CBL0137 in Subjects With Previously Treated Hematological Cancers L. Bryan Kelly Adams Heme Malignancies I

NLG-2106 NCT02835729

A Phase 1b/Randomized Phase 2a Trial of Indoximod in Combination with Idarubicin and Cytarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) J. Pantin Kelly Adams Acute Myeloid Leukemia Ia/IIb

5F9003 NCT02953509 

A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma L. Bryan Sandra Wall Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Ib/II

VT3996-201  NCT03397706

A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies Protocol Type: Treatment L. Bryan Sandra Wall Epstein-Barr Virus Associated Lymphoid Malignancies Ib/II

NU-16H07  NCT03077828 

(NU-16H07) Phase II Trial of Pembrolizumab in Combination with ICE Salvage Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma L. Bryan Sandra Wall Hodgkin Lymphoma II

BST002  NCT03435848

A Phase 2b, Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults with Newly-Diagnosed Acute Myeloid Leukemia, Not Eligible for Standard Induction Therapy V. Kota Sandra Wall AML IIb

2215-CL-0201 NCT02752035

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy J. Pantin Sandra Wall Acute Myeloid Leukemia II/III

A051301 NCT02443077

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype S. Ghamande Inquiries Large B-Cell Lymphoma III

B1371019   NCT03416179

A Randomized (1:1), Double-Blind, Multi-Center, Placebo Controlled Study Evaluating Intensive Chemotherapy With or Without Glasdegib (PF-04449913) or Azacitidine (Aza) With or Without Glasdegib in Patients With Previously Untreated Acute Myeloid Leukemia J. Cortes Sandra Wall Acute Myeloid Leukemia III

BMT-CTN-1506  NCT02997202

(2215-CL-0304) A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML J. Pantin Sandra Wall Acute Myeloid Leukemia III

EA4151 NCT03267433

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission S. Ghamande Sandra Wall  Mantle Cell Lymphoma III

FEDR-MF-001  NCT03755518

A Phase 3B, Multicenter, Single-Arm, Open-Label Safety and Efficacy Study of Fedratinib in Subjects With DIPSS-Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated with Ruxolitinib V. Kota Sandra Wall Myelofibrosis III

INCB-39110-309  NCT03584516

A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease V. Kota Sandra Wall Chronic Graft-Versus-Host Disease III

Ponatinib-3001  NCT03589326

A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib versus Imatinib, Administered in Combination with Reduced-intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) Protocol V. Kota Sandra Wall Acute Lymphoblastic Leukemia III

B1761031 ClinicalTrials.govNCT03727750 

A Single Arm, Open-label, Phase 4 Study Evaluating Qt Interval, Pharmacokinetics, And Safety Of Gemtuzumab Ozogamicin (Mylotarg (Trademarked)) as a Single-agent Regimen in Patients With Relapsed or Refractory Cd33-positive Acute Myeloid Leukemia V. Kota Sandra Wall Acute Myeloid Leukemia IV